Dow Jones received a payment from EQS/DGAP to publish this press release.
DGAP-Media / 2018-09-13 / 16:16
*Synthetically produced creatine can alleviate creatine deficiency syndrome*
At the first creatine deficiency syndrome (CCDS) symposium in Austin, Texas,
which AlzChem sponsored, several patients reported positive treatment
outcomes with creatine. Creatine is an endogenous substance produced in the
liver and kidneys and is essential for energy supply to the brain, muscles
and immune system. In people with creatine deficiency syndrome (Cerebral
Creatine Deficiency Syndrome, CCDS), the body's creatine metabolism does not
function properly, to word it simply, so that the brain is not supplied with
creatine. "This disorder is congenital and has various manifestations. The
body is either unable to produce creatine or to transport it to the cells.
The consequences are often serious: children with CCDS suffer from mental
and physical developmental disorders, and are usually unable to walk or
speak, often suffering from epilepsy, autism or mental disabilities,"
explains Dr. Ulrike Braun, Product Manager at AlzChem and symposium
participant.
Organized by the Association for Creatine Deficiencies (ACD), the event
aimed to bring affected people worldwide together for the first time to
promote exchange among each other and with experts from science and
industry. The association's work was also able to be communicated to
patients: to raise awareness of this disease, emphasize the importance of
describing the course of the disease for physicians and scientists, and
illustrate early diagnosis and treatment efforts. Creatine deficiency
diseases are often not recognized until late because it is a rare disease
without clearly standardized diagnostic methods and not often covered by
insurance, making it expensive. Early detection, ideally in newborns, and
appropriate therapy can alleviate the symptoms and significantly improve
children's quality of life. ACD is therefore committed to including CCDS in
general newborn screening.
"We estimate that approximately 500 CCDS cases have been diagnosed
worldwide. The actual number of people affected is likely to be
significantly higher, however, as the disorder is usually only found when
specifically looked for," reports Kim Tuminello, Co-Founder and Director of
Advocacy. In some of these cases, creatine as a dietary supplement can
partially or even completely compensate for the deficit - depending on the
age of the affected person - so that the patients develop completely
normally. "Creatine is an essential source of energy for every cell in the
body. The severity of creatine deficiency diseases illustrates the central
importance of creatine for the organism as well as for physical and mental
development. I am very proud that our product can help here," says Dr.
Ulrike Braun.
*Creatine from AlzChem*
Under the brand name Creapure(R), AlzChem offers a dietary supplement
consisting of the body's own substance creatine, which helps build muscle
and increase physical performance. AlzChem produces the pure creatine
monohydrate in Germany according to strict guidelines in food and
pharmaceutical quality with every batch thoroughly tested for purity.
The European Food Safety Authority (EFSA) has confirmed the positive effects
of creatine as a dietary supplement for athletes as well as for people over
55 years of age who exercise and strength train regularly.
*About AlzChem Group AG*
AlzChem Group AG is a vertically integrated manufacturer of various chemical
products based on the NCN chain. These are products with typical
nitrogen-carbon-nitrogen bonding that are used in a wide variety of
different industries. The company has a leading position in select niche
markets. The strategic focus of growth and the main focus of its extensive
research and development are on the business segment Specialty Chemicals.
The company has around 1,500 employees at four sites in Germany and three
other sites abroad.
End of Media Release
Issuer: AlzChem Group AG
Key word(s): Research/Technology
2018-09-13 Dissemination of a Press Release, transmitted by DGAP - a service
of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: AlzChem Group AG
Dr.-Albert-Frank-Str. 32
83308 Trostberg
Germany
Phone: +498621862888
Fax: +49862186502888
E-mail: ir@alzchem.com
Internet: www.alzchem.com
ISIN: DE000A0AHT46
WKN: A0AHT4
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Stuttgart
End of News DGAP Media
723451 2018-09-13
(END) Dow Jones Newswires
September 13, 2018 10:16 ET (14:16 GMT)
